



Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ESPR


| | |
|---------------|----------------------------|
| Last Trade: | 48.83 |
| Trade Time: | 4:00 PM ET Jul 25, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 9.40 - 50.52 |
| Volume | N/A |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 26, 2017

[Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe](#)

Jun 14, 2017

[Esperion to Present at the JMP Securities 2017 Life Sciences Conference](#)

May 31, 2017

[Esperion to Present at the Jefferies 2017 Global Healthcare Conference](#)

May 22, 2017

[Esperion Provides Update on Common Stock Trading Activity](#)

May 19, 2017

[Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 22, 2017

[Annual Report \(10-K\)](#)

Mar 6, 2017

[Proxy Statement \(DEF 14A\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)

Nov 3, 2016

[Quarterly Report \(10-Q\)](#)

Aug 4, 2016

[Quarterly Report \(10-Q\)](#)